Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LNS8801 |
Synonyms | |
Therapy Description |
LNS8801 is a selective G-protein coupled estrogen receptor (GPER) agonist, which activates GPER signaling and suppresses tumor-associated gene expression, potentially leading to the inhibition of tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LNS8801 | LNS 8801|LNS-8801|GPER agonist LNS8801 | LNS8801 is a selective G-protein coupled estrogen receptor (GPER) agonist, which activates GPER signaling and suppresses tumor-associated gene expression, potentially leading to the inhibition of tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |